Abstract
The development of reliable methods for the in vitro testing of sensitivity of cancer cells to various drugs has been a longstanding objective in cancer research and treatment. Early attempts to develop individualized chemotherapy were based on clonogenic assays. These attempts failed because of low plating efficiencies. Nonclonogenic assays, such as the MMT test or ATP determinations, are based on metabolic activities and do not reflect the ability of cells to proliferate. To detect proliferation, we selected a universal marker — ornithine decarboxylase (ODC), which is expressed early in the cell cycle and has a short half-life. This marker was detected in hematological cancer cells by quantitative immunohistochemical analyses using an ODC antibody and a FITC-linked second antibody. Drug resistance was detected in five patients, who subsequently died. Lymphocytes from normal individuals were sensitive to all drugs tested, whereas 33 leukemia and lymphoma patients showed different sensitivities to certain drugs. The method also permitted testing of the effect of new drugs on the proliferation of lymphocytes from hematological cancer patients. This test is sensitive, and 100–1,000 cells are required per assay, which can be completed within 2 days. It is very likely that the assay could also be used to test solid tumor patients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ahmann FR, Garewal HS, Schifman R, Celniker A, Rodney S (1987) Intracellular adenosine triphosphate as a measure of human tumor cell viability and drug modulated growth. In Vitro Cell Dev Biol 23:474–480
Assaraf YG, Drori S, Bachrach U, Shaugan-Labay V (1994) Determination of multidrug resistance levels in cultured mammalian cells using ornithine decarboxylase activity. Anal Biochem 216:97–109
Bachrach U, Shayovitz A, Marom Y, Ramu A, Ramu N (1994) Ornithine decarboxylase — a predictor for tumor chemosensitivity. Cell Mol Biol 40:957–964
Bellamy WT (1992) Prediction of response to drug therapy. A review of in vitro assays. Drug 44:690–708
Cohen SS (1998) A guide to the polyamines. Oxford University Press, New York
Cree IA, Kurbacher CM, Untch M, Sutherland LA, Hunter EM, Subedi AM, James EA, Dewer JA, Preece PE, Andreotti PE, Bruckner HW (1996) Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anti-Cancer Drugs 7:630–635
Cree IA, Kurbacher CM (1997) Individualizing chemotherapy for solid tumors — is there any alternative? Anti-Cancer Drugs 8:541–548
Cree IA, Neale MH, Myatt NE, de Takats PG, Hall P, Grant J, Kurbacher CM, Reinhold U, Neuber K, MacKie RN, Chana J, Weaver PC, Khoury GG, Sartori C, Andreotti PE (1999) Heterogeneity of chemosensitivity of metastatic melanoma. Anti-Cancer Drugs 10:437–444
Flamigni F, Facchini A, Capanni C, Stefanelli C, Tantini B, Caldarera CM (1999) p44/42 mitogen-activated protein kinase is involved in the expression of ornithine decarboxylase in leukemia L1210 cells. Biochem J 341:363–369
Hamburger AW, Salmon SE (1977) Primary bioassay of human tumor stem cells. Science 197:461–463
Konecny G, Crohns C, Pegram M, Felber M, Lude S, Kurbacher C, Cree IA, Hepp H, Untch M (2000) Correlation of drug response with ATP tumorchemosensitivity assay in primary stage III ovarian cancer. Gynecol Oncol 77:258–263
Kurbacher CM, Cree IA, Bruckner HW, Brenne U, Kurbacher JA, Muller K, Ackerman T, Gilster TJ, Wilhelm LM, Engel H, Mallmann PK, Andreotti PE (1998) Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anti-Cancer Drugs 9:51–57
Lundin A, Hasenson M, Persson J, Pousette A (1986) Estimation of biomass in growing cell lines by adenosine triphosphate assay. Meth Enzymol 133:27–42
Russell DH (1985) Ornithine decarboxylase: a key regulatory enzyme in normal and neoplastic growth. Drug Metab Rev 16:1–88
Salmon SE, Young L, Scuderi P, Clark B (1987) Antineoplastic effects of tumor necrosis factor alone and in combination with gamma-interferon on tumor biopsies in clonogenic assay. J Clin Oncol 5:1816–1821
Shayovits A, Bachrach U (1994) Immunochemical detection of ornithine decarboxylase in individual cells: potential application for in vitro chemosensitivity assays. J Histochem Cytochem 42:607–611
Shayovits A, Bachrach U (1995) Ornithine decarboxylase: an indicator for growth of NIH 3T3 fibroblasts and their c-Ha-ras transformant. Biochem Biophys Acta 1267:107–114
Smith TJ, Bodurtha JN (1995) Ethical considerations in oncology: balancing the interest of patients, oncologists and society. J Clin Oncol 13:2464–2470
Von-Hoff D, Clark GM, Stogdill BJ, Sarosdy MF, O'Brian MT, Casper JT, Mattox DE, Page CP, Cruz AB, Sandbach JF (1983) Prospective clinical trial of human tumor cloning system. Cancer Res 43:1926–1931
Wang Y, Ashkenazi YJ, Bachrach U (1999) In vitro chemosensitivity testing of hematological cancers: immunohistochemical detection of ornithine decarboxylase. Anti-Cancer Drugs 10:797–805
Wang Y, Or R, Bachrach U (2000) Chemosensitivity testing of hematological cancers using ornithine decarboxylase as a marker. Int J Med Biol Environ 28:51–56
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Bachrach, U., Wang, Y. (2003). In Vitro Chemosensitivity Testing of Hematological Cancer Patients: Detection of Ornithine Decarboxylase. In: Reinhold, U., Tilgen, W. (eds) Chemosensitivity Testing in Oncology. Recent Results in Cancer Research, vol 161. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-19022-3_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-19022-3_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62412-4
Online ISBN: 978-3-642-19022-3
eBook Packages: Springer Book Archive